Oramed CEO to Present at New York Biotechnology Association and The Israel Conference's Fast & Cool™ Session

  Oramed CEO to Present at New York Biotechnology Association and The Israel
                      Conference's Fast & Cool™ Session

PR Newswire

JERUSALEM, May 28, 2013

JERUSALEM, May 28, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a
developer of oral drug delivery systems, announced today that the company's
CEO, Nadav Kidron, has been invited to be a speaker at two key events in New
York and Los Angeles.

On Wednesday, May 29^th, Oramed will be featured at New York Biotechnology
Association's 22nd Annual Meeting at the Marriott Marquis Hotel in New York
City. Mr. Kidron will discuss the latest developments at Oramed regarding its
oral insulin technology.

On Friday, May 31^st, in Los Angeles, Mr. Kidron will be part of a panel at
The Israel Conference's Fast & Cool™ track featuring Medical Wonders.

About NYBA

NYBA is the leading advocate for advancing the success of the life science
industry in New York State and is its main representative to state policy
makers, the media, and other communities. NYBA's mission is to support the
development and growth of New York's life science industry, and serve its
members and the life science community by providing a network for information
exchange, shared services and collective action. NYBA's membership comprises
bioscience companies, world-class research institutions and related
professional services.

For more information: http://www.nyba.org

About The Israel Conference™

The Israel Conference™ spans two days and features leaders of significant
businesses that were founded in Israel, have R&D in Israel or do business in
Israel. Speakers represent the spirit of the inventiveness of the Israeli
market. The diverse cross-section of innovation and design from Israel
provides the attendees with an insider's understanding of the growth of both
public and privately held Israel-based companies as well as a front-row seat
to the technologies and products of tomorrow.

For more information: http://www.theisraelconference.org/

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery
solutions for drugs and vaccines currently delivered via injection.
Established in 2006, Oramed's technology is based on over 30 years of research
by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is
seeking to revolutionize the treatment of diabetes through its proprietary
flagship product, an orally ingestible insulin capsule (ORMD-0801) currently
initiating Phase 2 clinical trials under an Investigational New Drug
application with the U.S. Food and Drug Administration, and with its oral
exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a
trials. The company's corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release,
please visithttp://www.oramed.com

Forward-looking statements: This press release contains forward-looking
statements. For example, we are using forward-looking statements when we
discuss revolutionizing the treatment of diabetes and our oral insulin and
oral exenatide candidates approaching Phase 2 clinical trials under U.S. IND
and Phase 2a clinical trials, respectively. These forward-looking statements
are based on the current expectations of the management of Oramed only, and
are subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval or patent protection
for our product candidates; competition from other pharmaceutical or
biotechnology companies; and our ability to obtain additional funding required
to conduct our research, development and commercialization activities. In
addition, the following factors, among others, could cause actual results to
differ materially from those described in the forward-looking statements:
changes in technology and market requirements; delays or obstacles in
launching our clinical trials; changes in legislation; inability to timely
develop and introduce new technologies, products and applications; lack of
validation of our technology as we progress further and lack of acceptance of
our methods by the scientific community; inability to retain or attract key
employees whose knowledge is essential to the development of our products;
unforeseen scientific difficulties that may develop with our process; greater
cost of final product than anticipated; loss of market share and pressure on
pricing resulting from competition; laboratory results that do not translate
to equally good results in real settings; our patents may not be sufficient;
and final that products may harm recipients, all of which could cause the
actual results or performance of Oramed to differ materially from those
contemplated in such forward-looking statements. Except as otherwise required
by law, Oramed undertakes no obligation to publicly release any revisions to
these forward-looking statements to reflect events or circumstances after the
date hereof or to reflect the occurrence of unanticipated events. For a more
detailed description of the risks and uncertainties affecting Oramed,
reference is made to Oramed's reports filed from time to time with the
Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Mobile: +972-54-792-4438
Email: aviva@oramed.com

SOURCE Oramed Pharmaceuticals Inc.
Press spacebar to pause and continue. Press esc to stop.